Clinical Trial Update: CART123 + Ruxolitinib in Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating CART123 CAR T therapy in combination with ruxolitinib for relapsed or refractory acute myeloid leukemia; the study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CART123
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Pennsylvania | Conditions: Relapsed AML, Refractory AML | Phase 1 | Status: ACTIVE_NOT_RECRUITING